Perspectives on gene therapy in myotonic dystrophy type 1

Area of Science:

• Genetics
• Molecular Biology
• Neuromuscular Disorders

Background:

• Myotonic dystrophy type 1 (DM1) is an autosomal dominant neuromuscular disorder.
• Caused by a CTG expansion mutation in the DMPK gene's 3' UTR.
• Leads to nuclear retention of mutant DMPK mRNA, MBNL1 protein trapping, and CELF1 stabilization.

Purpose of the Study:

• To review experimental advances in cell-based and animal models for DM1 therapeutic development.
• To discuss the potential clinical application of these therapeutic strategies.
• To highlight emerging alternative strategies beyond targeting mutant DMPK RNA.

Main Methods:

• Review of cell-based and animal models for DM1.
• Analysis of therapeutic strategies targeting mutant RNA (antisense oligonucleotides, small chemical compounds).
• Exploration of alternative strategies not directly targeting mutant DMPK RNA.

Main Results:

• Experimental advances in cell and animal models show promise for DM1 therapies.
• Targeting mutant RNA is a primary strategy, aiming to reduce toxic effects.
• Emerging alternative strategies offer new avenues for reversing DM1 pathology.

Conclusions:

• Current DM1 treatments are limited to symptom management.
• Therapeutic strategies targeting mutant RNA show potential for clinical trials.
• Alternative approaches are emerging to reverse DM1 features without directly targeting mutant RNA.